Medico Intercontinental Ltd. engages in the business of financing, trading and investment in shares and securities. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2016-06-17. The firm is engaged in the business of pharmaceutical products. The company provides platform platform to all research based biopharmaceuticals companies. The firm's product categories include gastro, uro, nutrition, cosmetology, health devices, hospital, and other areas. Its products include ACIFACT-BLI, ACIFACT-P, ACIFACT-SP (ALU-ALU), ALBECTIN, ALFACARE - D3, ARSUFACT Combokit, BALOFACT, CYCLOFACT 400, UDIFACT 150, XOFACT - 4, ZIFT SL - 250, ZYMIX, ARGIFACT, CLIANCIACT POWDER, RELIEVE CZ, VOLIREX SPRAY, RACIMAX SACHET, PERMACT, OROFACT, KTZ, FEMYACT, LIVOFACT, ZYMIX SY, ULTRATONE SY, ALBECTIN SUS, BECOFACT DROPS, MEFACT P SUS, ONCARE SOLUTION, OFCARE-FORTE SUS, PRODOM PLUS DRY SY., PRODOM CV SY., RELIBEN SUSP., ZIFT SUSP.-200 MGCIPACT EYE DROP, CIPACT EYE DROP, I-NORM NASAL DROPS, LUBRIACT, MCM TEAR DROPS, OFCARE EYE DROPS, OLOFACT, TIMOCARE, ORODENT, OROFACT-PASTE(lamy), and OROFACT MOUTH ULCER GEL.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.